IP
The startup has developed a brain infusion technology that enables precise and continuous drug delivery directly into the central nervous system for the treatment of neurodegenerative diseases. This targeted administration enhances treatment efficacy and safety, allowing healthcare professionals to manage these conditions more effectively.
Updated 3 months ago
Funding
$4.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup has developed a brain infusion technology that enables precise and continuous drug delivery directly into the central nervous system for the treatment of neurodegenerative diseases. This targeted administration enhances treatment efficacy and safety, allowing healthcare professionals to manage these conditions more effectively.